Correlation of Technical and Adjunctive Factors with Quantitative Tumor Reduction in Children Undergoing Selective Ophthalmic Artery Infusion Chemotherapy for Retinoblastoma

References

1. 1.↵
   1. Abruzzo TA,
   2. Geller J,
   3. Kimbrough D, et al

   . Adjunctive techniques for optimization of ocular hemodynamics and biological response to therapy in children undergoing ophthalmic artery infusion chemotherapy. J Neurointerv Surg 2015;7:770–76 doi:10.1136/neurintsurg-2014-011295 pmid:25179634

   Abstract/FREE Full Text
2. 2.↵
   1. Bertelli E,
   2. Leonini S,
   3. Galimberti D, et al

   . Hemodynamic and anatomic variations require an adaptable approach during intra-arterial chemotherapy for intra-ocular retinoblastoma: alternative routes, strategies and follow up. AJNR Am J Neuroradiol 2016;37:1289–95 doi:10.3174/ajnr.A4741 pmid:26915566

   Abstract/FREE Full Text
3. 3.↵
   1. Gündüz K,
   2. Günalp I,
   3. Yalçindağ N, et al

   . Causes of chemoreduction failure in retinoblastoma and analysis of associated factors leading to eventual treatment with external beam radiotherapy and enucleation. Ophthalmology 2004;111:1917–24 doi:10.1016/j.ophtha.2004.04.016 pmid:15465557

   CrossRefPubMed
4. 4.↵
   1. Eckman WW,
   2. Patlack CS,
   3. Fenstermacher JD

   , A critical evaluation of the principles governing the advantages of intra-arterial infusion. J Pharmakinet Biopharm 1974;2:257–85 doi:10.1007/BF01059765 pmid:4452940

   CrossRefPubMed
5. 5.↵
   1. Fenstermacher JD,
   2. Cowles AL

   . Theoretic limitations of intracarotid infusions in brain tumor chemotherapy. Cancer Treat Rep 1977;61:519–26 pmid:884689

   PubMedWeb of Science
6. 6.↵
   1. Shields CL,
   2. Kaliki S,
   3. Shah SU, et al

   . Minimial exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma. Opthalmol 2012;119:188–92 doi:10.1016/j.ophtha.2011.06.036 pmid:21975042

   CrossRefPubMed
7. 7.↵
   1. Michaels ST,
   2. Abruzzo TA,
   3. Augsburger JJ

   , et al. Selective ophthalmic artery infusion chemotherapy for advanced intraocular retinoblastoma: CCHMC early experience. J Pediatr Hematol Oncol 2016;38:65–69 doi:10.1097/MPH.0000000000000471 pmid:26583615

   CrossRefPubMed
8. 8.↵
   1. Feng L,
   2. Fitzsimmons BF,
   3. Young WL, et al

   . Intraarterially administered verapamil as adjunct therapy for cerebral vasospasm: safety and 2-year experience. AJNR Am J Neuroradiol 2002;23:1284–90 pmid:12223366

   Abstract/FREE Full Text
9. 9.↵
   1. Krishnakumar S,
   2. Mallikarjuna K,
   3. Desai N, et al

   . Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol 2004;88:1521–26 doi:10.1136/bjo.2004.047928 pmid:15548804

   Abstract/FREE Full Text
10. 10.↵
    1. Kamburoğlu G,
    2. Kiratli H,
    3. Söylemezoğlu F, et al

    . Clinicopathological parameters and expression of P-glycoprotein and MRP-1 in retinoblastoma. Ophthalmic Res 2007;39:191–97 doi:10.1159/000104680 pmid:17596751

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Seigel GM,
    2. Campbell LM,
    3. Narayan M, et al

    . Basic and clinical research on the therapeutic effect of intervention in primary liver cancer by targeted intra-arterial verapamil infusion. Cell Biochem Biophys 2012;62:59–67 doi:10.1007/s12013-011-9259-4 pmid:21830124

    CrossRefPubMed
12. 12.↵
    1. Filho JP,
    2. Correa ZM,
    3. Odashiro AN, et al

    . Histopathological features and P-glycoprotein expression in retinoblastoma. Invest Ophthalmol Vis Sci 2005;46:3478–83 doi:10.1167/iovs.04-1290 pmid:16186322

    Abstract/FREE Full Text
13. 13.↵
    1. Kuhne A,
    2. Tzvetkov MV,
    3. Hagos Y, et al

    . Influx and efflux as determinants of melphalan cytotoxicity: resistance to melphalan in MDR1 overexpressing tumor cell lines. Biochem Pharmacol 2009;78:45–53 doi:10.1016/j.bcp.2009.03.026 pmid:19447222

    CrossRefPubMed
14. 14.↵
    1. Larrivee B,
    2. Averill DA

    . Melphalan resistance and photoaffinity labelling of P-glycoprotein in multidrug-resistant Chinese hamster ovary cells: reversal of resistance by cyclosporin A and hyperthermia. Biochem Pharmacol 1999;58:291–302 doi:10.1016/S0006-2952(99)00094-5 pmid:10423171

    CrossRefPubMed
15. 15.↵
    1. Raaijmakers HG,
    2. Izquierdo MA,
    3. Lokhorst HM, et al

    . Lung-resistance-related protein expression is a negative predictive factor for response to conventional low but not to intensified dose alkylating chemotherapy in multiple myeloma. Blood 1998;91:1029–36 pmid:9446666

    Abstract/FREE Full Text
16. 16.↵
    1. Huang J,
    2. Duan Q,
    3. Fan P, et al

    . Clinical evaluation of targeted arterial infusion of verapamil in the interventional chemotherapy of primary hepatocellular carcinoma. Cell Biochem Biophys 2011;59:127–32 doi:10.1007/s12013-010-9125-9 pmid:20963512

    CrossRefPubMed
17. 17.↵
    1. Cairo MS,
    2. Siegel S,
    3. Anas N, et al

    . Clinical trial of continuous infusion verapamil, bolus vinblastine, and continuous infusion VP-16 in drug-resistant pediatric tumors. Cancer Res 1989;49:1063–66 pmid:2536292

    Abstract/FREE Full Text
18. 18.↵
    1. Han YH,
    2. Sweet DH,
    3. Hu DN, et al

    . Characterization of a novel cationic drug transporter in human retinal pigment epithelial cells. J Pharmacol Exp Ther 2001;296:450–57 pmid:11160630

    Abstract/FREE Full Text
19. 19.↵
    1. Chapy H,
    2. Saubamea B,
    3. Tournier N, et al

    . Blood-brain and retinal barriers show dissimilar ABC transporter impacts and concealed effect of P glycoprotein on a novel verapamil influx carrier. Br J Pharmacol 2016;173:497–510 doi:10.1111/bph.13376 pmid:26507673

    CrossRefPubMed
20. 20.↵
    1. LaPage MJ,
    2. Bradley DJ,
    3. Dick M

    . Verapamil in infants: an exaggerated fear? Pediatr Cardiol 2013;34:1532–34 doi:10.1007/s00246-013-0739-8 pmid:23800976

    CrossRefPubMed
21. 21.↵
    1. Kehr J,
    2. Binfield A,
    3. Maxwell F, et al

    . Fascicular tachycardia in infancy and the use of verapamil: a case series and literature review. Arch Dis Child 2019;104:789–92 doi:10.1136/archdischild-2018-315617 pmid:31005896

    Abstract/FREE Full Text
22. 22.↵
    1. Phillips TJ,
    2. McGuirk SP,
    3. Chahal HK, et al

    . Autonomic cardio-respiratory reflex reactions and superselective ophthalmic arterial chemotherapy for retinoblastoma. Paediatr Anaesth 2013;23:940–55 doi:10.1111/pan.12162 pmid:23668238

    CrossRefPubMed
23. 23.↵
    1. Abramson DH,
    2. Daniels AB,
    3. Marr BP, et al

    . Intra-arterial chemotherapy (ophthalmic artery chemosurgery) for group D retinoblastoma. PLoS One 2016;11:e0146582 doi:10.1371/journal.pone.0146582 pmid:26756643

    CrossRefPubMed
24. 24.↵
    1. Abruzzo TA,
    2. Patino M,
    3. Leach J, et al

    . Cerebral vasoconstriction triggered by sympathomimetic drugs during chemotherapy. Pediatr Neurol 2013;48:139–42 doi:10.1016/j.pediatrneurol.2012.10.005 pmid:23337008

    CrossRefPubMed
25. 25.↵
    1. Bode H,
    2. Wais U

    . Age dependence of flow velocities in basal cerebral arteries. Arch Dis Child 1988;63:606–11 doi:10.1136/adc.63.6.606 pmid:3389890

    Abstract/FREE Full Text
26. 26.↵
    1. Area C,
    2. Yen CJ,
    3. Chevez-Barrios P, et al

    . Technical and anatomical factors affecting intra-arterial chemotherapy fluoroscopy time and radiation dose for intraocular retinoblastoma. J Neurointerv Surg 2019;11:1273–76 doi:10.1136/neurintsurg-2019-014910 pmid:31197028

    Abstract/FREE Full Text